Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON-IPF
NCT06097260Phase 2Terminated
- Sponsor
- Pliant Therapeutics
- Start
- Nov 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 2, randomised, double-blind trial of bexotegrast in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Pliant Therapeutics. Primary endpoint: Change From Baseline in Forced Vital Capacity at 52 weeks. Started Nov 2023; status: terminated.
02
Drugs
bexotegrast
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06097260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06097260.